Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · View financials
Decision snapshot: DOC stock price vs ZS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ZS's multiple
Needs ZS P/E.
Implied fair value · at DOC's multiple
Needs EPS (TTM) is negative, DOC P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: DOC FY 2025 (ended Dec 31, 2025) · ZS FY 2026 (ended Jul 31, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
Healthpeak Properties, Inc. · implied price per share
Bear
-$5.48
Base
-$6.44
Bull
-$7.41
Zscaler Inc · implied price per share
Bear
-$3.61
Base
-$4.25
Bull
-$4.89
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
1.31x
0.44x
Net debt / EBITDA
Leverage against operating earnings
14.48x
1.77x
Cash and equivalents
Liquid reserves on the balance sheet
$492.29M
$928.35M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
WELLTOWER INC.
DOC vs WELL
Ventas, Inc.
DOC vs VTR
ALEXANDRIA REAL ESTATE EQUITIES, INC.
DOC vs ARE
SL GREEN REALTY CORP
DOC vs SLG
Palo Alto Networks Inc
DOC vs PANW
CrowdStrike Holdings, Inc.
DOC vs CRWD
Okta, Inc.
DOC vs OKTA
Cloudflare, Inc.
DOC vs NET
Fortinet, Inc.
DOC vs FTNT
$9.85B
$1.14B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe DOC can sustain profitability while improving growth without adding much leverage, then consider the stock as a relative-value buy because it already screens cheaper than ZS on P/S and is below ZS-implied price by 65.3%, but the weaker growth and leverage profile argue for caution.
DOC trades at 5.3x P/S versus ZS at 8.9x, so on a sales basis DOC is the cheaper name even though the provided implied price suggests meaningful upside. DOC’s current price of $21.89 sits above the DCF range of $6.06 to $8.20 but below the historical band upper end of $24.08, which makes the stock look fairly valued to slightly rich versus history while still discounted versus ZS-implied view.
Supporting Metrics
